Reviews/Iron Status/Alternate-day dosing improves absorption
Ida · IRON-IDA-02 · v2
The evidence on this specific question comes down to one study that actually measured how much iron the body absorbed using labelled iron [1]. That study found people absorbed more iron when they took supplements every other day rather than every day, at the same total dose. A plausible biological reason supports this: daily dosing raises the blood hormone hepcidin, which blocks iron uptake, and alternate-day dosing keeps it lower [1][3][5]. However, only that one study measured absorption directly, it was open-label (participants and researchers knew who got what), and several other trials measuring blood counts found the absorption edge did not translate into faster recovery from anaemia [3][9][11]. The panel judged the narrow absorption claim well supported but limited by reliance on a single direct study and the gap between absorption and clinical benefit.
One isotope-based study [1] directly measured iron absorption and found alternate-day dosing gave higher cumulative fractional absorption (21.8% vs 16.3%, p=0.0013) and higher total absorption (175.3 vs 131.0 mg, p=0.0010) than consecutive-day dosing at equal total dose. The mechanism is coherent: serum hepcidin was higher on consecutive days [1], and lower hepcidin on alternate-day dosing is corroborated in an independent double-blind trial [3] and in children [5]. However, the direct absorption measurement rests entirely on [1], and the clinical-outcome trials measure haemoglobin and iron status rather than absorption [2][6][8][9]. At equal total dose one trial found no difference in serum ferritin [3], and other trials found daily dosing produced greater haematological gains [9] or better met iron demand [11]. The contested point: The division is between the direct absorption surrogate and downstream clinical benefit: [1] shows more iron is absorbed per total dose on alternate days, but [3] found no higher ferritin at equal total dose and [9] found daily dosing gave greater haematological improvements. Whether the measured absorption advantage carries through to faster anaemia correction is where the evidence pulls apart.
All 12 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Iron Status, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Direct absorption evidence rests entirely on a single open-label study [1]; the apparent corroboration [7][10] merely restates it and independent isotopic replication is absent.
Fractional absorption is a mechanistic surrogate; at equal total doses [3] found no higher ferritin, and [9]/[11] favour daily dosing for haematological/iron-status endpoints, so the absorption edge does not carry to clinical benefit.
Where it remains uncertain. The absorption gain is a surrogate: [3] found no ferritin difference at equal total dose and [9] found daily dosing produced greater haematological improvements.
Aleatory
The only direct absorption study [1] enrolled 40 and 20 women, leaving the effect estimate subject to sampling variability.
Epistemic
Isotopic absorption was measured in one study [1]; [7] and [10] restate it rather than replicate, so independent confirmation is absent.
Inferential
Higher fractional absorption partly reflects lower dosing frequency; whether more iron is delivered per unit time rather than per dose is not cleanly separable [1].
The load-bearing papers from a corpus of 12, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct primary evidence that alternate-day dosing yields higher fractional and total iron absorption at equal total dose
“Providing iron supplements on alternate days and in single doses optimises iron absorption and might be a preferable dosing regimen.”
Panel auditInternal validity: high · scope of inference: Iron-depleted (ferritin ≤25 μg/L) non-anaemic women aged 18-40 in Switzerland; absorption efficiency, not clinical outcomes.Key limitations: open-label / unmasked allocation · non-anaemic iron-depleted women only · absorption endpoint, not haemoglobin outcome · authors say findings need confirmation in anaemic patients
Corroborates the mechanism (lower hepcidin on alternate days) that would raise absorption, though ferritin did not differ
“median serum hepcidin was 3.0 nM (IQR 2.0-5.0) versus 1.9 nM (1.4-2.9) (P < 0.0001)”
Panel auditInternal validity: high · scope of inference: Young iron-depleted Swiss women (ferritin ≤30 μg/L); iron stores/deficiency and tolerability over 6 months, not absorption efficiency.Key limitations: absorption not directly measured · ferritin (retention) showed no benefit while hepcidin favoured alternate-day · non-anaemic depleted women only
Counterpoint showing the absorption advantage does not reliably translate to superior haematological outcomes
“In iron-deficient WRA in an LMIC setting, daily OIS (60 mg) for 14 days was more effective than equivalent amounts on alternate days in improving hematological parameters.”
Panel auditInternal validity: medium · scope of inference: Non-pregnant iron-deficient women aged 18-45 in an LMIC; haematological indices, not absorption.Key limitations: no absorption endpoint measured · short 14-day intervention · the fractional-absorption statement is background from other studies, not this trial's result
Soluble transferrin receptor rose significantly with alternate-day (worsening iron status) but not with daily dosing, which the authors interpret as daily dosing best meeting iron demand.
Panel auditInternal validity: medium · scope of inference: Non-anaemic pregnant women, whose physiology may dominate dosing effects; iron-status trajectory, not fractional absorption.Key limitations: pregnancy population, likely outside the claim's typical scope · sTfR is an iron-status marker, not absorption · small three-arm split · hepcidin declined in all groups
4 of 12 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A significant, mechanistically coherent direct absorption finding supports the claim, but single-study dependence and a surrogate-to-outcome gap prevent the Established tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent isotopic replication of absorption. The entire direct claim rests on one open-label study [1]; no other corpus paper measures absorption directly. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A blinded, isotope-labelled RCT measuring fractional and total absorption at equal total dose in an independent population.
Open question: Does the higher fractional and total absorption seen with alternate-day dosing replicate under blinded, isotope-labelled conditions? Why it is still open: The only direct measurement [1] is a single open-label study, with [7] and [10] restating rather than replicating it.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19